Detalhe da pesquisa
1.
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Sci Transl Med
; 16(734): eadg7962, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38354229
2.
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Oncoimmunology
; 12(1): 2205336, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37114242
3.
Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.
Oncoimmunology
; 11(1): 2054106, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35355682
4.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
iScience
; 25(9): 104958, 2022 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36072551
5.
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Cancer Immunol Res
; 10(4): 498-511, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362043
6.
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Clin Cancer Res
; 27(20): 5457-5464, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108185
7.
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Clin Cancer Res
; 27(11): 3167-3177, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33785484
8.
Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential.
Front Oncol
; 10: 593848, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33680923